Innate Pharma SA (IPH) Stock Statistics & Valuation Metrics

Innate Pharma SA has a market cap or net worth of €156.26M. The enterprise value is €142.85M.

Innate Pharma SA has 93,921,860 shares outstanding. The number of shares has decreased by -2.65% in one year.

Innate Pharma SA’s return on equity (ROE) is 2.27 and return on invested capital (ROIC) is -146.05%.

The current PE Ratio of Innate Pharma SA is ―. Innate Pharma SA’s PEG ratio is 0.30.

In the last 12 months, Innate Pharma SA had revenue of 2.79M and earned -49.18M in profits. Earnings per share was -0.55.

In the last 12 months, operating cash flow was -52.76M and capital expenditures -140.00K, giving a free cash flow of -52.90M billion.

Innate Pharma SA pays an annual dividend of ―, resulting in a dividend yield of ―

Innate Pharma SA upcoming earnings date is Sep 17, 2026, Before Open (Confirmed).

Innate Pharma SA as a current ratio of 1.27, with Debt / Equity ratio of -104.00%

In the past 12 months, Innate Pharma SA has paid -6.21M in taxes.

Innate Pharma SA EV to EBITDA ratio is -2.46, with an EV/FCF ratio of -2.60.

Innate Pharma SA has €34.31M in cash and marketable securities with €22.57M in debt, giving a net cash position of €11.74M billion.

Gross margin is 100.00%, with operating margin of -2058.02%, and net profit margin of -1764.51%.

The average price target for Innate Pharma SA is ―, which is 11.43% higher than the current price. The consensus rating is ―